Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athenex Inc ATNXQ

Healthcare Biotechnology
Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is... see more

Recent & Breaking News (GREY:ATNXQ)

Athenex Pharmaceutical Division Receives FDA Clearance to Import Potassium Chloride Injection Concentrate to Address U.S. Drug Shortage

GlobeNewswire August 9, 2018

Athenex, Inc. to Report Second Quarter Earnings Results on August 14, 2018

GlobeNewswire August 3, 2018

Athenex Announces That Two Phase 3 Pivotal Efficacy Studies of KX2-391 in Actinic Keratosis Achieved Their Primary Endpoints

GlobeNewswire July 26, 2018

Athenex Announces Axis Therapeutics Has Entered into a MOU with the Hong Kong Polytechnic University to Set Up a Joint Research Center on Cancer Immunotherapy

GlobeNewswire July 18, 2018

Athenex Names Timothy Cook as Senior Vice President of Global Commercial Oncology

GlobeNewswire July 9, 2018

Athenex Announces Pipeline Expansion Initiatives in Conjunction with a Strategic Investment of $100 million by Perceptive Advisors

GlobeNewswire July 2, 2018

Athenex Announces Appointment to Board of Directors

GlobeNewswire June 15, 2018

Athenex Names Christina Wang as Vice President of Clinical Operations and Corporate Development, Asia Pacific

GlobeNewswire June 4, 2018

Athenex Announces Poster Presentations at ASCO Annual Meeting

GlobeNewswire June 4, 2018

Athenex, Inc. Announces First Quarter 2018 Results

GlobeNewswire May 14, 2018

Athenex to Present at Deutsche Bank’s 43rd Annual Health Care Conference

GlobeNewswire May 8, 2018

Athenex, Inc. to Report First Quarter Earnings Results on May 14, 2018

GlobeNewswire May 3, 2018

Athenex, Inc. Announces Transition of James Zukin from Board of Directors to Advisory Role

GlobeNewswire April 30, 2018

Athenex, Inc. Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of Angiosarcoma

GlobeNewswire April 19, 2018

Athenex to Present at the 17th Annual Needham Healthcare Conference

GlobeNewswire March 27, 2018

Athenex, Inc. Announces Fourth Quarter and Full-Year 2017 Results

GlobeNewswire March 26, 2018

Earnings Scheduled For March 26, 2018

Benzinga.com  March 26, 2018

Athenex, Inc. to Report Fourth Quarter and Full Year 2017 Earnings Results on March 26, 2018

GlobeNewswire February 26, 2018

Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis in the American Academy of Dermatology Meeting

GlobeNewswire February 20, 2018

Athenex to Present at 2018 RBC Capital Markets Healthcare Conference

GlobeNewswire February 16, 2018